Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH
Repurposed Promise In Competitive Indication
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
You may also be interested in...
The CEO of South Korea's Hanmi Pharm shares experiences around licensing deals and turning around returned assets, identifying "great opportunities" in the near term for the country's pharma and biotech sectors as global partners continue to hunt for novel products and technologies.
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.